Thanks to the recently-conducted basket trials, clinical studies in which patients affected by several tumor types harboring the same genomic aberration received a specific targeted treatment, the tyrosine kinase inhibitor (TKI) larotrectinib was granted accelerated approval by Food and Drug Administration (FDA) for cancers displaying NTRK pathogenic fusions while entrectinib, a TKI targeting NTRK, ALK and ROS1 fusions, was granted priority review by FDA [17,18]. This evidence concerns the gene ROS1 and neoplasm.